Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer.
Latest Presentation
Investor Alerts
Receive the latest alerts via email.
Contact IR
Curis, Inc.
128 Spring Street
Building C- Suite 500
Lexington, MA 02421
Phone: 617-503-6500
Email: ir@curis.com
Transfer Agent
Computershare
150 Royall St., Suite 101
Canton, MA 02021
URL: www.computershare.com/investor
Phone: 877-810-2248
This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.